May 21, 2024

IMMUNOTHERAPY

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma CLN-619 Monoclonal Antibody
1 min read

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food...
Read More
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial "Bispecific Antibody CTX-8371 Research"
2 min read

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple...
Read More
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer "Ovarian Cancer Treatment Clinical Trial"
2 min read

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

 IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces...
Read More
Dragonfly Announces Clinical Collaboration Exploring Combinations Between Dragonfly’s DF1001 HER-2 TriNKET® and Gilead’s Trodelvy® in Two Cancer Indications Dragonfly Therapeutics Clinical Collaboration Announcement
2 min read

Dragonfly Announces Clinical Collaboration Exploring Combinations Between Dragonfly’s DF1001 HER-2 TriNKET® and Gilead’s Trodelvy® in Two Cancer Indications

Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced a new clinical collaboration designed...
Read More
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer "Pancreatic Cancer Treatment"
2 min read

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at...
Read More

You may have missed

IMA to Organize Conference on “Multispecialities Cardio Reno Metabolic & HF in Women” Tomorrow Multispecialities Cardio Reno Metabolic Conference & HF in Women
3 min read

IMA to Organize Conference on “Multispecialities Cardio Reno Metabolic & HF in Women” Tomorrow

May 18, 2024
Justrite® Develops Groundbreaking Solution for the Growing Dangers of Lithium-Ion Battery Fires Justrite Lithium-Ion Battery Charging Cabinet
2 min read

Justrite® Develops Groundbreaking Solution for the Growing Dangers of Lithium-Ion Battery Fires

May 18, 2024
Bot Image, Inc. introduced its Prostate Cancer detection, diagnosis, and screening software at urologist meeting in San Antonio, Texas Prostate Cancer Detection Software ProstatID
2 min read

Bot Image, Inc. introduced its Prostate Cancer detection, diagnosis, and screening software at urologist meeting in San Antonio, Texas

May 18, 2024
WS Audiology Strengthens Commitment to Innovation with New R&D Centre of Excellence in Hyderabad WS Audiology R&D Centre of Excellence in Hyderabad
2 min read

WS Audiology Strengthens Commitment to Innovation with New R&D Centre of Excellence in Hyderabad

May 18, 2024